The median survival time was 43 months.
中位生存时间为43个月。
The median survival time was 5, 16, 28 months, respectively.
三种手术方式的中位生存期分别为5,16,28个月。
Moreover, median survival time after confirmation of initial relapse was 2.6 months.
此外，在证实初期复发后平均存活时间为2.6个月。
The median survival time was significantly prolonged in the experimental group (P< 0.01).
实验组与对照组相比有显著性意义（P<0． 01）。
When told that the median survival time for someone with this disease was only 8 months, he did some research.
当被告知患上此种疾病的人平均存活时间仅为八个月的时间，他做了一些研究。
Results: the overall 5-year survival of the patients was 82.0% and the median survival time was 100.0 months.
结果：本组盆腔淋巴结阴性患者的五年总体生存率为82 0 %，中位生存时间10 0 0月。
Twenty-five patients survived over 8 months with the median survival time 16 months and life quality were improved.
生存者存活期均超过8个月，中位生存期1 6月，生活质量改善。
The median survival time for patients treated with radiation was 17.5 months, compared to 16.4 months for those who had surgery.
接受放疗病人的中位生存时间是17.5个月，而接受手术病人的中位生存时间是16.4个月。
Methods a mouse model of disseminated candidiasis was established and the survival rate and median survival time after administration of agent were detected.
方法建立小鼠系统性白念珠菌感染模型，观察给药后小鼠中位生存时间，并检测给药后小鼠肾脏菌落形成单位计数。
The median survival time of 19 patients with simple ovary metastasis was 31 months, while that of 43 patients with ovary and other organ metastasis was 21 months.
其中19例单纯卵巢转移患者的中位生存时间31个月，43例卵巢合并其他部位转移患者的中位生存时间21个月。
Median survival time for patients with an EGFR exon 19 deletion in serum was also substantially higher than in those with L858R mutations (32 months vs 14 months).
血浆中egfr外显子19删除患者的中位生存期要明显好于那些存在L 858r变异患者(32个月相对14个月)。
Besides, compare median survival time with survival rate for 5 cases of chemotherapy group and 10 cases of non-chemotherapy group (the high-risk group of MDS patients). Results: 1.
另外，对5例化疗患者和10例非化疗患者(均为高危组MDS患者)进行中位生存期和生存率比较。
The median time of survival may increase as patients choose more definitive, rather than palliative, treatment.
接受更多疗法的患者比姑息治疗的患者生存率要高。
Median survival reflects one time point along the survival curve and does not measure the overall survival benefit.
生存中值反映了生存曲线上的一个时间点，并不能测量总的生存期。
After hepatectomy with embolectomy and biliary duct drainage, the survival time was 5-46 months and the survival median time was 23.5 months.
肝切除术、胆管取癌栓及胆道引流术病人术后生存时间为5 ~ 4 6个月，中位生存期为2 3 5个月。
After hepatectomy with embolectomy and biliary duct drainage, the survival time was 5-46 months and the survival median time was 23.5 months.
肝切除术、胆管取癌栓及胆道引流术病人术后生存时间为5 ~ 4 6个月，中位生存期为2 3 5个月。
应用推荐